Materialise (MTLS) Corporate Presentation summary
Event summary combining transcript, slides, and related documents.
Corporate Presentation summary
6 Jun, 2025Company overview
Materialise is a global leader in 3D printing software and services, with operations in 21 countries and over 2,500 employees.
The company operates three business units: Software, Manufacturing, and Medical, serving diverse industries including healthcare, aerospace, automotive, and consumer goods.
In 2024, Materialise printed over 2.1 million parts and helped more than 60,000 patients with its medical solutions.
The management team is led by CEO Brigitte de Vet-Veithen, supported by executives overseeing operations, strategy, technology, and business segments.
Materialise emphasizes sustainability, customization, and cross-functional synergies as key differentiators.
Industry and market trends
3D printing, or additive manufacturing, is experiencing consistent double-digit annual growth, with the market projected to reach $150.2 billion by 2032.
The technology enables decentralized, fast, flexible, and sustainable production, offering design freedom and mass personalization.
Adoption is gradual, described as a "Slow Revolution," but its transformative potential spans multiple industries.
Business segments and solutions
Software: Materialise provides solutions for optimizing additive manufacturing processes, with 92% of the largest metal AM system manufacturers and 85% of automotive companies as clients.
Manufacturing: Offers rapid prototyping, small series production, mass customization, and spare parts, with over 2.1 million parts printed in 2024.
Medical: Delivers personalized healthcare solutions, including surgical planning, patient-specific models, and implants, helping over 60,000 patients annually.
Latest events from Materialise
- Medical segment drove 4.3% revenue growth, but profits fell; 2025 guidance unchanged.MTLS
Q1 202517 Mar 2026 - Q4 revenue up 6.8%, Medical segment leads, 2026 EBIT guided at EUR 10–12 million.MTLS
Q4 202519 Feb 2026 - Record Q2 revenue and profit, led by Medical growth and strategic medical technology expansion.MTLS
Q2 20242 Feb 2026 - Q3 2024 revenue up 14.2% to €68.7M, led by Medical; full-year outlook reaffirmed.MTLS
Q3 202418 Jan 2026 - Medical growth drove profit gains, but Manufacturing and Software faced headwinds in 2024.MTLS
Q4 202423 Dec 2025 - Medical segment growth offsets overall revenue decline; cost control sustains profitability.MTLS
Q2 202516 Nov 2025 - Q3 2025 revenue fell 3.5% as Medical growth offset declines in Manufacturing and Software.MTLS
Q3 202529 Oct 2025